Premium
Multiantigenic Nanovaccines: Multiantigenic Nanoformulations Activate Anticancer Immunity Depending on Size (Adv. Funct. Mater. 49/2019)
Author(s) -
Li Shengxian,
Feng Xiangru,
Wang Jixue,
Xu Weiguo,
Islam Mohammad Ariful,
Sun Tianmeng,
Xie Zhigang,
Wang Chunxi,
Ding Jianxun,
Chen Xuesi
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201970336
Subject(s) - materials science , imiquimod , cancer immunotherapy , immunity , lymph , cross presentation , hela , nanotechnology , cancer research , immunotherapy , antigen presentation , immune system , t cell , cell , biology , immunology , medicine , biochemistry , psychiatry
In article number 1903391, Jianxun Ding and co‐workers develop three multiantigenic nanovaccines of different sizes for cancer immunotherapy, which are composed of various imiquimod‐loaded poly(lactic‐co‐glycolic acid) nanoparticles and a cancer cell membrane coating. The smallest nanovaccine shows rapid migration to the draining lymph nodes, achieves efficient antigen presentation to T lymphocytes, and induces antitumor immunity.